Kimaya Dixit's picture

FDA Opens Up Social Media to Pharma Companies with New Guidelines


When it comes to social media in the pharma [[wysiwyg_imageupload:174:]]
space, PR and communications professionals have fought a very long and laborious battle. Fortunately, the U.S. Food and Drug Administration (FDA) has finally come through with new and officially issued guidance for pharma's interactive marketing activities online. While this certainly clarity to an otherwise dark and restrictive social media-pharma terrain, there are a few bumps along the way to keep in mind.

First and foremost, there is no denying that the somewhat unrestricted freedom to tweet, post, blog, pin, etc. is right in line with where the future of real-time reporting and health PR is headed. These guidelines will most likely lead to real-time interactive marketing initiatives quickly slipping into PR strategies for pharma companies, both big and small. Read full post »

Maria Sherstneva's picture

Healthcare Communications in Russia


Every PR specialist who starts working in[[wysiwyg_imageupload:169:]]
healthcare communications knows that it is on the one hand a great responsibility to promote something that saves people’s lives and really makes a difference in the world but on the other hand is a great challenge. Many medical topics are difficult to pitch and to have discussed in the media.  In addition, the area is highly regulated not only by governmental institutions but also by the clients themselves.  Under the auspices of Ketchum’s Global Scholar program, I recently had the opportunity to travel from Moscow to Ketchum’s New York office with a view to exchange our healthcare expertise, knowledge and insights.

Having a basic idea of the U.S. healthcare system already gave me an understanding of the dramatic differences between our countries. But I could not believe it influenced the approach to communications so much. Learning about the extent of FDA oversight in the U.S.I saw that there were far more distinct boundaries to work within. Read full post »

Chartése  Day's picture

Pharma’s New Cliffhanger: Protecting Corporate Reputation in the Face of a Prescription Drug Abuse Epidemic


For the pharmaceutical industry, most have [[wysiwyg_imageupload:132:height=126,width=191]]
focused on the crisis of the patent cliffhanger: the loss of more than $30 billion in revenue due to patent expiration of prescription drugs once dubbed “blockbusters.”

However, a greater crisis awaits - one that impacts not only a company’s bottom-line, but also a pharmaceutical company’s greatest asset: its corporate reputation. Companies must brace themselves to handle the industry’s role in combating the prescription drug abuse epidemic.

While most major causes of preventable death are declining, drug overdoses are an exception. And, opioids seem to bear the brunt of the blame. A 2011 report from the Centers for Disease Control and Prevention revealed that most drug-related deaths were not the result of illicit drugs, such as heroin or cocaine, but instead were the result of prescription pain medicines, mainly opioids.  Inappropriate use of opioids caused nearly 342,000 emergency department visits in 2009, according to government figures. The drugs were blamed for 16,000 deaths that year, up from 14,800 in 2008. Read full post »

Andrew Lamb's picture

A European Perspective on Social Media and the FDA’s New Guidance

1 comment

While it falls short of the comprehensive guidance [[wysiwyg_imageupload:115:]]
on social media that many were hoping for, the FDA’s new document on responding to unsolicited requests does have an interest and relevance for those working in healthcare communications on the other side of the Atlantic.

Of course, no digital project is completely ‘local’ and Europeans should always have half an eye on developments elsewhere in the world. More importantly though, the FDA has given us a useful clue to what regulators are thinking and the issues they face in coming up with clear rules for the rapidly evolving environment of the web and social media. It could also set the tone for European guidance, if and when it appears.

The most significant aspect of the FDA’s new document is that: Read full post »

In: Digital & Social Media  /   filed under: EU | FDA | pharma | Social Media | UK
Suzannah Palinkas's picture

We Must First Ask the Question - What Do We Want to Accomplish?


It seems simple enough and a logical first step to [[wysiwyg_imageupload:114:]]
planning anything but so many times, across multiple disciplines, we hear:

“We need a Facebook page.”

“We need to have a blog.”

“We need to be Tweeting.”

But why? At a recent social media conference, specifically in the Pharma space, the question and principle came up multiple times… we need to start by asking a few simple questions. What are we trying to accomplish? Reaching who? What then are we going to do with the information? Why do we need to be in the social media space?

One can’t deny that online vehicles are growing rapidly, exponentially expanding, and that social media channels are just too large a communication vehicle to ignore. Even so, there has to be the right fit between what a company wants to accomplish online and the vehicles through which it achieves those goals. And it seems that sometimes those key questions haven’t been answered, and the result is an inappropriate or useless execution that simply checks a box. Read full post »